Committed to Innovation
Our clear focus on medical devices for minimally invasive treatment of valvular heart disease makes us experts.
We have a holistic approach based on our heritage in the design and development of unique technologies leveraging new advances in engineering. It is also based on our expertise in manufacturing and marketing such devices, and on our commitment to an Evidenced Based Medicine approach.
New Valve Technology stands for knowledge, experience, expertise and a pioneering spirit. It is the distinctive sign of robust and practice-oriented R&D capabilities that pave the way for the creation of innovative medical technologies. Our aim is to place these innovations where they belong: in the hands of expert physicians.
Our current structural heart flagship product, the ALLEGRA™ transcatheter aortic valve implantation system, stemmed from this strong in-house R&D pipeline and manufacturing capabilities. It is a self-expanding supra-annular transcatheter aortic valve which presents unique design features and similar event rates compared to contemporary devices. It received CE mark in 2017 and further received CE approval for Valve-in-Valve indication on 29 April 2020.
We invest in shaping the future and we are committed to further validate our innovative technology through a comprehensive clinical program.
An overview of our clinical trials with the ALLEGRA™ TAVI system:
- “First-In-Man” and “NAUTILUS” (CE approval studies)
- “VIVALL” (extension for the valve-in-valve indication)
- “FOLLOW” (post-market study)
Further information and the outcomes of our research will be available on this page soon.